Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes
Xinqi Wu(Dana-Farber Brigham Cancer Center), F. Stephen Hodi(Harvard University), Margaret A. Shipp(Broad Institute), Jing Ouyang(Nanjing Agricultural University), Glenn Dranoff(Dana-Farber Cancer Institute), Matthias Piesche(Catholic University of the Maule), Donald P. Lawrence(Massachusetts General Hospital), David F. McDermott(Beth Israel Deaconess Medical Center), Jun Zhou(Brigham and Women's Hospital), Anita Giobbie‐Hurder(Institute for Tourism), Xiaoyun Liao(Bristol-Myers Squibb (Germany)), Erin M. Connolly(Dana-Farber Cancer Institute), Jingjing Li(Weifang Medical University), Scott J. Rodig(Brigham and Women's Hospital), Gëorge F. Murphy(Brigham and Women's Hospital)
Cited by 68
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k